Update on Atrial Shunt Therapy for Treatment of Heart Failure is a research paper published in Structural Heart (2022). On theSindex it has a DataRank of 0.442. It has been cited 18 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.442
From this paper's citation signal
Citation Network Contribution
0
Citation network not refreshed for this result
This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.
Learn more about DataRank methodology →National Institutes of Health
Grant: R01 HL107577
National Institutes of Health
Grant: R01 HL127028
National Institutes of Health
Grant: R01 HL140731
National Institutes of Health
Grant: R01 HL149423
National Institutes of Health
Grant: U54 HL160273
National Institutes of Health
Grant: 5R01HL140731-03
Machine learning for the automated identification and tracking of rare myocardial diseases
National Institutes of Health
Grant: 5R01HL107577-06
Determinants, Trajectories, and Consequences of Abnormal Cardiac Mechanics
National Institutes of Health
Grant: 5R01HL127028-03
Transition from Risk Factors to Early HF: Prevalence, Pathogenesis, and Phenomics
National Institutes of Health
Grant: 5R01HL149423-04
Precision Medicine for Dilated Cardiomyopathy—Novel Assessment of Cardiac Mechanics via Speckle Tracking Echocardiography to Identify Early Phenotypes
National Institutes of Health
Grant: 1U54HL160273-01
HeartShare DeCODE-HF: Data translation center to Combine Omics, Deep phenotyping, and Electronic health records for Heart Failure subtypes and treatment targets
AstraZeneca
Cytokinetics
United Therapeutics Corporation
Boehringer Ingelheim
Medtronic
Edwards Lifesciences
Eli Lilly and Company
Pfizer
FWCI
2.31
Citation Percentile
0.9%
Citation Trend
Fields of Study
Keywords